You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201321 - 201330 of 207712 results
  1. Pharmacological evaluation of MLR-1023: Studies to confirm efficacy, establish a

    SBC: Melior Discovery, Inc.            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goals of this project are to develop a biomarker for MLR-1023 in order to validate Lyn kinase as a molecular target for treatment of Type II diabetes (T2D) and use the biomarker to understand the pharmacokinetic/pharmacodynamic (PK/PD) disconnect in order to optimize a dosing regimen in clinical trials. These goals will be accomplished by showing MLR-1023 t ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Wireless Tibial Nerve Stimulation Therapy for Overactive Bladder

    SBC: ROSELLINI SCIENTIFIC, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this SBIR Phase 1 proposal is to determine the feasibility of wireless neuromodulation for controlling bladder function. Overactive bladder (OAB) affects about 16.5% of the adult population in both the United States and Europe. Percutaneous electrical stimulation of the posterior tibial nerve (PTN) recently emerged as an effective, yet minimally inv ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. A Novel Peptide Therapeutic for Obesity

    SBC: VIRTICI LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): The goal of this project is to develop a novel peptide therapeutic, GLP-1-5, for the treatment of obesity. Today, one-third of adults in the United States (US) are obese, with an estimated annual healthcare burden of approximately 150 billion. By 2030, it is projected that over 50% of adults in the US will be obese with a yearly healthcare burden expected to e ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Development of a new anti-inflammatory peptide for treatment of type II diabetes

    SBC: SERPIN PHARMA, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Type II diabetes (T2DM) affects more than 5% of the population in Western countries. In the US alone, about 23.6M children and adults have diabetes, and the associated cost was estimated to 174 billion in 2007. The rise in T2DM prevalence is linked to the dramatically increased incidence of obesity, which now affects about a third of the adult US population. H ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Target Identification of Proteins and Peptides Capable of Recruitment of Brown Ad

    SBC: ENERGESIS PHARMACEUTICALS INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Obesity has reached epidemic proportions in the U.S. and plays a major role in the development of type 2 diabetes, dyslipidemia, and cardiovascular disease. While most weight loss agents rely on suppressing appetite toreduce caloric intake, strategies that can safely enhance metabolic rate, a previously unrealized approach to weight loss or weight maintenance, ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Chronically Acting CFTR Inhibitor Discovery for Secretory Diarrhea and ADPKD

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDDK

    Project Summary Abstract DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen a collection of small molecular compounds on a human epithelial cell platform expressing physiologically relevant levels of the wild-type Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) to discover a new class of therapeutic drugs for secretory disease ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Transitional Care Program for Medicaid Patients and Integrated Care Teams

    SBC: PHCC LP            Topic: NIDDK

    DESCRIPTION (provided by applicant): Preventable hospital admissions and readmissions are indicators of health system fragmentation and are associated with suboptimal patient outcomes and avoidable costs of care. Readmissions often result from leaving discharged patients to their own devices, unable to follow instructions they didn't understand, and not taking medications or getting the nece ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Identification of Novel Small Molecule AMPK Modulators

    SBC: CurlBio LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Western life style has spurred the growth of numerous obesity related disorders including metabolic syndrome, type 2 diabetes and certain types of cancers to epidemic proportions. Maintaining cellular energy is a basicbiological need mediated in part through amp-activated protein kinase (AMPK), therefore controlling cellular energy metabolism can play a role in ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Peer-to-Peer Mentoring Platform for Diabetes Management, Training and Support

    SBC: InquisitHealth, Inc.            Topic: NIDDK

    ABSTRACT The Specific Aim of this proposal is to test the feasibility of developing a web-based peer mentor training and mentor-mentee matching system to help patients better manage their diabetes through mentoring. Effective self-management of diabetesis the key to improving diabetes outcomes and reducing costs. Self-management includes medication adherence, self-monitoring, healthy eating, and ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. The V-Needle: A Failsafe Protection against Needle Dislodgement during Dialysis

    SBC: HEMOTEK            Topic: NIDDK

    DESCRIPTION (provided by applicant): On average, more than 1,800,000 sessions of hemodialysis are performed each week in the U.S. by more than 600,000 end stage renal disease (ESRD) patients. A grave danger to any of these patients is Venous Needle Dislodgement (VND), a catastrophic and potentially deadly unintended removal of the needle pumping blood back into the body. Incident rate estimates va ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government